Clinical Research Directory
Browse clinical research sites, groups, and studies.
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Sponsor: Genentech, Inc.
Summary
The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).
Official title: An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2026-11-02
Completion Date
2030-03-29
Last Updated
2026-11-05
Healthy Volunteers
No
Conditions
Interventions
Cevostamab
Participants will receive cevostamab IV as per the schedule given in the protocol.
Tocilizumab
Tocilizumab may be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.
Locations (11)
Royal Melbourne Hospital
Parkville, Victoria, Australia
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clnicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital das Clínicas FMRP-USP
Ribeirão Preto, São Paulo, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
Sao Jose Rio Preto, São Paulo, Brazil
Peking University First Hospital
Beijing, Beijing Municipality, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
Hopital Rangueil
Toulouse, Haute Garonne, France
Istituto Clinico Humanitas
Rozzano, Lombardy, Italy
Hospital Universitario Virgen Macarena
Seville, Spain